FDA will not be able to implement its proposed OTC monograph reform and user fee rules on Oct. 1, the start of US federal fiscal year 2018, because those changes were contingent on Congress passing enabling legislation.
So far, such legislation has not made it beyond the discussion stage, either as an independent bill or as part of the FDA Reauthorization Act, which renewed existing pharmaceutical and...